According to the review of approximately 300,000 patients by Sikander Ailawadhi, MD, Oncologist, Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, and colleagues, there was also significant heterogeneity in practice patterns across all characteristics studied.

An interrupted time-series analysis by David Merola, PharmD candidate, Bernard J. Dunn School of Pharmacy, Shenandoah University, Winchester, VA, and colleagues, showed a significant increase in missed workdays per month after the initial diagnosis of multiple myeloma among patients who received oral or injectable cancer therapy.

Treatment with ivosidenib, an IDH1 inhibitor, resulted in an objective response rate of 41.6% in a phase 1 dose-escalation and expansion clinical trial of patients with relapsed or refractory acute myeloid leukemia and IDH1 mutation, according to data presented at ASH 2017.


Results 1 - 3 of 3